Effect of Nardostachys jatamansi DC on clinical symptoms of functional dyspepcia /postprandial distress syndrome.

comparison the effect of hydro alcoholic extract of Nardostachys jatamansi DC with the effect of hydro alcoholic extract of Nardostachys jatamansi DC with Dompridon® on the symptoms of patients with functional dyspepsia® on the symptoms of patients with functional dyspepsia/post postprandial distress syndrome.

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017022332738N1

Enrollment

128

Registered

2017-11-12

Start date

2017-09-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

functional dyspepcia. Dyspepsia

Interventions

Intervention 1: Intervention grope:Nardostachys jatamansi DC capsuls, 400 mgr after each meal(TDS)T for one month. Intervention 2: control grope:Domperidone capsules,10 mgr after each meal(TDS)T for o

Treatment - Drugs

Intervention grope:Nardostachys jatamansi DC capsuls, 400 mgr after each meal(TDS)T for one month.

control grope:Domperidone capsules,10 mgr after each meal(TDS)T for one month.

Eligibility

Sex/Gender

All

Age

25 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: patients aged 25 to 60 years; with a diagnosis of functional dyspepsia (based on ROME IIIcriteria ) and no history of peptic ulcer and reflux disease; normal endoscopic with no specific pathologic finding and H. pylori negative; no treatment before the current study(new patient); there is no underlying medical conditions; including heart failure; kidney failure and uremic disease; cirrhosis; diabetes; hypothyroidism and hyperthyroidism; no history of abdominal surgery; no history of chemotherapy and radiation or exposure radioactive radiation. Exclusion criteria: use of chemical and herbal drugs with gastrointestinal effects; pregnancy and lactation; patients disagreement to continue the project and lack of access to patients

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Total score of gastrointestinal symptom rating scale. Timepoint: before intervention , the scond and forth weeks of the intervention,one month after the end of intervention. Method of measurement: Gastrointestinal symptom rating scale.	—

Secondary

Measure	Time frame
Drug complication. Timepoint: intervention period and after tretment. Method of measurement: questioner.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMorteza Mojahedi

Faculty of Traditional Medicine, BabolUivercity Of Medical Sciences

mirzapor@yahoo.com+98 11 3219 4730

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026